News and Events
Stay informed about RECOVER’s Long COVID research by reading the latest news and participating in upcoming events.
Featured News Item
RECOVER-VITAL clinical trial finds no benefit of extended duration of PAXLOVID for Long COVID
RECOVER researchers conducted a clinical trial to test whether PAXLOVID, an antiviral drug, could reduce Long COVID symptoms when taken for 15 or 25 days. The study enrolled 959 adults with Long COVID at 69 sites across the US.
News Release
38 Results
38 Results
Electronic health records are an important tool to address Long COVID questions
Electronic health records (EHRs) give researchers the ability to look at large groups of people and understand how Long COVID behaves over a long period of time.
Feature
RECOVER Research Update: September 2025
Recent RECOVER research has revealed important links between Long COVID and a range of other physical, mental, and emotional health conditions.
Research Update
Electronic health record study examines how COVID-19 severity impacts risk of autoimmune diseases
Researchers found that severe COVID-19 can cause a strong immune response, which can cause the body’s immune system to attack itself and lead to new autoimmune diseases.
Feature
RECOVER’s mid-year milestones: A look at 2025 progress
This year, RECOVER researchers continue to publish results from research studies that deepen our understanding of Long COVID. RECOVER studies continue, with 2 clinical trials expected to reach enrollment goals this summer.
Feature
RECOVER Research Update: June 2025
By studying millions of patients’ electronic health records (EHRs), RECOVER researchers are gaining understanding about who Long COVID affects, how it affects them, and why some people are more likely to be affected than others.
Research Update
RECOVER study provides new insights on the relationship between pregnancy and Long COVID
Recent RECOVER findings provide insights into how changes to the immune system during pregnancy may affect a woman’s risk of developing Long COVID.
Feature
RECOVER EHR study provides additional information about pediatric Long COVID symptoms
Researchers identified six common groups of symptoms experienced by children and adolescents with Long COVID.
Feature
R3 Seminar Recap: Understanding metformin use and Long COVID and ME/CFS following COVID-19 infection: Insights from two studies
A recent RECOVER Research Review (R3) Seminar held May 13 spotlighted research presented by Carolyn Bramante, MD, MPH (University of Minnesota) and Steve Johnson, PhD (University of Minnesota) exploring how metformin, a widely prescribed medication primarily used to manage type 2 diabetes, may help reduce the risk of Long COVID. The seminar also featured a presentation from Suzanne Vernon, PhD (Bateman Horne Center) on research examining the risk of developing myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) following a COVID-19 infection.
R3 Seminar Recap